INTRODUCTION
Numerous studies have been recently reported on tissue engineering1,2), materials for scaffold3,4) and cytocompatibility of biomaterials5-8).
Cells, scaffolds and physiologically active substances are crucial to tissue engineering.
Blood vessels are also necessary for nutrients to enable cells to survive, and physiologically active substances for angiogenesis are required.
The process of angiogenesis involves endothelial cells attaching to the basement membranes of blood vessels, then migrating, proliferating, and forming tube-like structures9).
Folkman mentioned that it was now helpful to think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth10). Conversely, angiogenesis is concerned with various diseases, such as cancer, rheumatoid arthritis, psoriasis, arteriosclerosis, proliferative retinopathies and periodontal disease9,11,12) Various studies have shown that these cellular responses are tightly regulated by signals from various growth factors and cytokines including vascular endothelial growth factor (VEGF)11,12), basic fibroblast growth factor (b-FGF)13), hepatocyte growth factor (HGF)14,15) and interleukin 816, 17) . Since these growth factors are recombinants of growth factors (proteins) extracted from animals and comprise sequences of 100-200 amino acids, application in humans may carry risks of unpredictable problems such as infectious diseases, adverse effects and immunological allergens. Meanwhile peptides have merits of low antigenecity and easy metabolism, because they are composed of 2-10 amino acids and have low molecular weight.
Furthermore, designing amino acid sequences is easy, and efficient synthetic methods and detection technologies have already been established.
If any peptide was found to have the same function as growth factors, the peptide will be applied enormously to medical care.
Although peptides with some physiologically active functions have been found18,19), no positive results have yet been reported for peptides causing angiogenesis.
Recently, the novel binding sequence Ser-Val-ValTyr-Gly-Leu-Arg (SVVYGLR) was found adjacent to the RGD sequence in osteopontin molecule following thrombin cleavage, and might be important in pathological conditions20).
Our previous study clarified that SVVYGLR activates adhesion, migration and tube formation by endothelial cells in vitro21). Alanine scan assay allows the identification of key amino acids in peptides by using mutant peptides in which alanine is substituted for each amino acid of the peptide in turn.
The present study confirmed angiogenesis due to synthetic SVVYGLR in vivo and identified the key amino acid in the peptide using alanine scan. 
MATERIALS AND METHODS

1) Synthesis and characterization
of SVVYGLR SVVYGLR was synthesized on PEG-PS graft copolymer beads as support with a high efficiency solidphase method using a PSSM-8 automatic peptide synthesizer (Shimadzu, Japan). After assembly of the peptide chain, side chain protection was removed to leave a resin-bound peptide. The peptide was characterized by high performance liquid chromatography-mass spectrometry (Shimadzu, Japan). This indicates that the synthetic product represented pure SVVYGLR peptide.
A total of 7 mutant peptides (AVVYGLR, SAVYGLR, SVAYGLR, SVVAGLR, SVVYALR, SVVYGAR and SVVYGLA) were also synthesized by substituting each amino acid of SVVYGLR for alanine (A). These 7 mutant peptides were also confirmed as pure peptides by matching theoretical mass values for each mutant peptide. 
2) Dorsal air sac (DAS) assay
RESULTS
1) DAS assay
Angiogenesis is characterized by spiral and immature blood vessels. Fig. 3 shows representative results for DAS assay. Fig. 3 a using PBS solution showed no spiral and immature blood vessels, unlike VEGF and SVVYGLR solutions (Fig. 3 b and 3 c, respectively) . Fig. 4 shows quantitative results for angiogenesis. Angiogenesis were significantly higher for VEGF and SVVYGLR than for PBS (Control).
However, angiogenesis did not differ significantly between VEGF and SVVYGLR.
2) Alanine scan assay (Ala-scan assay) Fig. 5 shows representative results for DAS assay using solutions of the 7 mutant peptides (Ala-scan assay).
SVVAGLR resulted in no spiral and immature blood vessels (Fig. 5 d) , but the remaining mutant peptides displayed varying levels of spiral and immature blood vessels. Fig. 6 shows quantitative results for angiogenesis by the 7 mutant peptides. Angiogenesis was significantly lower for SVVAGLR than for all other mutant peptides. Our previous study clarified that 0.02ƒÊg/mL of SVVYGLR activates adhesion, migration and tube formation by endothelial cells in vitro21~. In the present study, in vivo angiogenesis was evaluated using the DAS assay. Mean ( ± SD) grade of angiogenesis was 0.00±0.00 for Control, 1.50±0.60 for VEGF and 2.00 ± 0.00 for SVVYGLR.
VEGF is known as a growth factor with strong angiogenic properties. Surprisingly; ~SVVYGLR displayed approximately the same level of angiogenesis as VEGF. It is also worth that the ability of angiogenesis in vivo was recognized at same content of SVVYGLR peptide with high adhesion and migration activity to endothelial cells in vitro.
Numerous studies have shown that growth factors like VEGF, HGF and bFGF possess angiogenic functions.
Compared with these growth factors, peptides offer 3 advantages.
First, peptides are more easily metabolized than growth factors, since peptides with lower molecular weight (several hundred Daltons) are considered to have a higher metabolic rate than growth factors with higher molecular weight (several dozen kilo Daltons) . Second, although the decomposition products from growth factors are unknown, those resulting from peptides breakdown are readily identifiable, since peptides are composed of only a few amino acids. This may indicate a high biocompatibility of peptides. Third, new peptides are easily designed by changing part of the amino acid sequence to improve physiological activity.
Then, to determine amino acids crucial to the angiogenic properties of SVVYGLR, alanine-scan assay (DAS assay for 7 mutant peptides) was performed.
SVVAGLR, substituting the fourth amino acid Y (tyrosine) for A (alanine) did not possess result in any spiral and immature blood vessels. This means that tyrosine represents a key amino acid for angiogenesis, while terminal amino acids S (serine) and R (arginine) are unimportant for angiogenesis. This information offers the possibility of developing more effective mutant peptides by substitution Y (tyrosine) for other amino acids.
Furthermore, the S and R terminal amino acids might be usable as conjugating sites with carrier proteins (e.g., gelatine) or scaffold materials. 
